Commentary on oncolytic viruses: past, present, and future
Whither oncolytic viruses? From the peak of their popularity in the early 2000s, when the ONYX-015 adenovirus had just entered the clinic, and then again in 2015 when the Food and Drug Administration-approved talimogene laherparepvec (also known as OncoVEXGM-CSF), which briefly revived interest, onc...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-12-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/11/12/e007905.full |
| _version_ | 1827149761468170240 |
|---|---|
| author | Christopher Larson Bryan Oronsky Tony R Reid |
| author_facet | Christopher Larson Bryan Oronsky Tony R Reid |
| author_sort | Christopher Larson |
| collection | DOAJ |
| description | Whither oncolytic viruses? From the peak of their popularity in the early 2000s, when the ONYX-015 adenovirus had just entered the clinic, and then again in 2015 when the Food and Drug Administration-approved talimogene laherparepvec (also known as OncoVEXGM-CSF), which briefly revived interest, oncolytic viruses (OVs) have mostly fallen out of favor despite the many pharmaceutical companies with OVs in development.This commentary enumerates and addresses the core conceptions, perceptions, and misconceptions that characterize the current ‘trough of disillusionment’ in which the field of anticancer virotherapy finds itself and suggests reasons for optimism. |
| first_indexed | 2024-03-08T16:58:25Z |
| format | Article |
| id | doaj.art-eef8e99024d94edf91e48f537d74df9e |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2025-03-20T21:23:19Z |
| publishDate | 2023-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-eef8e99024d94edf91e48f537d74df9e2024-08-12T09:20:10ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-12-01111210.1136/jitc-2023-007905Commentary on oncolytic viruses: past, present, and futureChristopher Larson0Bryan Oronsky1Tony R Reid2EpicentRx Inc, La Jolla, USAEpicentRx Inc, La Jolla, California, USAEpicentRx Inc, La Jolla, USAWhither oncolytic viruses? From the peak of their popularity in the early 2000s, when the ONYX-015 adenovirus had just entered the clinic, and then again in 2015 when the Food and Drug Administration-approved talimogene laherparepvec (also known as OncoVEXGM-CSF), which briefly revived interest, oncolytic viruses (OVs) have mostly fallen out of favor despite the many pharmaceutical companies with OVs in development.This commentary enumerates and addresses the core conceptions, perceptions, and misconceptions that characterize the current ‘trough of disillusionment’ in which the field of anticancer virotherapy finds itself and suggests reasons for optimism.https://jitc.bmj.com/content/11/12/e007905.full |
| spellingShingle | Christopher Larson Bryan Oronsky Tony R Reid Commentary on oncolytic viruses: past, present, and future Journal for ImmunoTherapy of Cancer |
| title | Commentary on oncolytic viruses: past, present, and future |
| title_full | Commentary on oncolytic viruses: past, present, and future |
| title_fullStr | Commentary on oncolytic viruses: past, present, and future |
| title_full_unstemmed | Commentary on oncolytic viruses: past, present, and future |
| title_short | Commentary on oncolytic viruses: past, present, and future |
| title_sort | commentary on oncolytic viruses past present and future |
| url | https://jitc.bmj.com/content/11/12/e007905.full |
| work_keys_str_mv | AT christopherlarson commentaryononcolyticvirusespastpresentandfuture AT bryanoronsky commentaryononcolyticvirusespastpresentandfuture AT tonyrreid commentaryononcolyticvirusespastpresentandfuture |